We analyzed 30 eyes of 28 patients who previously underwent Boston type 1 keratoprosthesis surgery at our institution between 2004 and 2008.
D ecades of effort have been spent in attempts to develop a modern keratoprosthesis to treat patients with corneal blindness and a poor prognosis for penetrating keratoplasty (PK). These include patients with repeated graft failure and patients with severe ocular surface diseases such as Stevens-Johnson syndrome, ocular cicatricial pemphigoid (OCP), chemical burns, limbal stem cell deficiency, severe keratoconjunctivitis sicca, and severe corneal neovascularization. 1, 2 A variety of designs have been studied with variable success. One of the most commonly employed devices in the United States is the Boston type 1 keratoprosthesis. The first series of patients with this design was reported in 1974, and the device was eventually approved in 1992 by the Food and Drug Administration for marketing in the United States. 3, 4 Case series of the Boston type 1 keratoprosthesis from other centers have been reported previously. 5, 6 In 2006, Zerbe et al 7 reported a large multicenter series of Boston type 1 keratoprosthesis patients and extensively analyzed preoperative, intraoperative, and postoperative characteristics. This report provided a comprehensive analysis of these patients, but average follow-up was brief, limiting the ability of the study to determine these high-risk patients' long-term success and prognosis with the Boston type 1 keratoprosthesis. The purpose of this study is to present the Boston type 1 keratoprosthesis experience at University of California Davis (UC Davis) with long-term follow-up and to compare these findings with this initial multicenter report.
MATERIALS AND METHODS

Surgical Procedure
The Boston type 1 keratoprosthesis is obtained from the Massachusetts Eye and Ear Infirmary (Boston). Details of the device and the surgical technique for implantation technique have been described in detail. 7 The surgical technique and postoperative management implemented at UC Davis do not differ significantly from that described in the initial Boston Keratoprosthesis Study Group report.
Data Collection and Analysis
We collected data retrospectively by chart review after the institutional review board approval. We included all Boston type 1 keratoprosthesis implantations performed at UC Davis over a 4-year period (May 2004-2008) ( Table 1) . Six of these eyes were included in the initial Boston Keratoprosthesis Study Group report. 
RESULTS
Patient Demographics
Fifty-seven percent (57%) of patients were male and 43% were female. The average age of the patients was 56.5 years (range, 3-87 years). Each eye had undergone on average of 2.57 prior corneal transplants (range, 0-7; SD, 1.68; mode, 3). The most common preoperative corneal diagnosis was failed graft (26 eyes, 87%), followed by chemical injury (3 eyes, 10%), and Stevens-Johnson syndrome (1 eye, 3%) ( Table 1) . Preoperative visual acuity (VA)ranged from 20/150 to light perception (median, count fingers) ( Fig. 1 ).
Intraoperative Variables
We used the pseudophakic Boston type 1 keratoprosthesis in 93% of eyes (28/30) and the aphakic model in 7% of eyes (2/30) ( Table 1) . Concomitant procedures included cataract extraction with intraocular lens implantation (9 cases), tarsorrhaphy (3 cases), fornix reconstruction (1 case), Baerveldt tube shunt implantation (1 case), and a temporary keratoprosthesis with pars plana vitrectomy (1 case).
Glaucoma and Keratoprosthesis
Preoperatively, 20 eyes (60%) had glaucoma, and these patients were using an average of 1.5 medications. Nine eyes (30%) had a prior tube shunt, and 4 eyes (13%) had a prior trabeculectomy. After implantation of the keratoprosthesis, elevated intraocular pressure (as estimated by tactile tensions) was present in 8 eyes (27%) and progression of the underlying glaucoma occurred in 2 eyes (7%), primarily because of poor compliance with medication regimens and loss to follow-up (Table 1) . Serial optic nerve head photographs and visual field 
VA Outcomes
Postoperatively, VA improved significantly in the vast majority of patients (Figs. 2, 3) . The number of patients with best-corrected visual acuity (BCVA) 20/200 or better increased from 14% preoperatively to 77% postoperatively. Twenty-three percent (23%) had postoperative vision of 20/40 or better (Table 1 ).
In the subgroup of 16 eyes followed for at least 1 year after keratoprosthesis implantation (mean follow-up, 28 months; range, 12-48 months; SD, 12.8 months; median 24 months), vision was $20/200 in 75% of eyes and $20/40 in 25% of eyes (Fig. 4) . The anatomic retention rate of the initial keratoprosthesis was 81.3% (13/16) in this subgroup. Decreased vision was most common because of end-stage glaucoma or other posterior segment pathology.
Subgroup analyses of visual and anatomic outcomes based on select preoperative diagnoses (graft failure from noncicatrizing disease, chemical burns, and Stevens-Johnson syndrome) are shown in Table 2 .
Postoperative Complications and Management
The most common nonsurgical complication was retroprosthetic membrane formation [13 eyes (43% of eyes), of which 7 (53%) were treated with yttrium-aluminum-garnet (YAG) laser membranectomy] ( Table 1) . One eye (7.7%) required surgical membranectomy, and the others required no treatment. One patient developed a retroprosthetic membrane that we could not open with the laser but has deferred surgical membranectomy (Fig. 5 ).
Other nonsurgical complications encountered after Boston type 1 keratoprosthesis implantation included increased intraocular pressure (8 eyes, 27%), corneal melt (5 eyes, 17%), infectious keratitis (5 eyes, 17%), endophthalmitis (3 eyes, 10%), progression of glaucoma (2 eyes, 7%), choroidal effusion or hemorrhage (2 eyes, 7%), vitreous hemorrhage (1 eye, 3%), iris prolapse (1 eye, 3%), sterile vitritis (1 eye, 3%), posterior capsular opacity (1 eye, 3%), high myopic refraction (1 eye, 3%), hyphema (1 eye, 3%), and phthisis bulbi (1 eye, 3%). All 3 patients with endophthalmitis were using topical vancomycin at the time of presentation. Each patient was culture positive for a different organism with 1 patient growing each of the following bacteria: Pseudomonas aeruginosa, Proteus mirabilis, and Haemophilus influenzae. Other procedures performed after initial Boston type 1 keratoprosthesis implantation included keratoprosthesis replacement [10 occurrences, 5 eyes (18% of patients)], YAG laser capsulotomy (3 eyes, 10%), intravitreal antibiotics (3 eyes, 10%), corneal patch graft (3 eyes, 10%), temporary keratoprosthesis with pars plana vitrectomy (2 eyes, 7%), tarsorrhaphy (2 eyes, 7%), broken suture replacement (1 eye, 3%), subconjunctival antibiotics (1 eye, 3%), surgical membranectomy (1 eye, 3%), drainage of choroidal hemorrhage (1 eye, 3%), and keratoprosthesis removal followed by PK (1 eye, 3%).
The retention rate of the initial keratoprosthesis at an average follow-up of 19 months (range, 1-48 months; SD, 13.8 months; median, 13 months) was 83.3%, with only 5 failures. The causes of failure included corneal melting in 4 eyes and infectious keratitis in 1 eye. Of these 5 eyes 
DISCUSSION
Preoperative Characteristics
The majority of patients undergoing Boston type 1 keratoprosthesis implantation at UC Davis had multiple prior failed grafts. Only a few high-risk patients (3 eyes with alkali burn and 1 eye with Stevens-Johnson syndrome) received the keratoprosthesis without prior transplant. A previous study of Boston keratoprosthesis patients demonstrated that eyes with prior transplant failure because of noncicatricial causes had the best prognosis (83% of those achieving vision of at least 20/200 maintained it at 2 years), followed by OCP (72%), chemical burns (64%), and Stevens-Johnson syndrome (33%).
Because of the poor prognosis in Stevens-Johnson syndrome, the authors recommended avoiding Boston type 1 keratoprosthesis implantation in these patients. 8 Zerbe et al 7 also reported good outcomes for patients with chemical burns and noncicatrizing graft failure [94% and 90%, respectively, of eyes achieving at least 20/200 vision maintained it at the last follow-up (average 8.5 months)]. This report also confirmed a less favorable prognosis with OCP (75% of eyes maintained at least 20/200) and Stevens-Johnson syndrome (only one eye enrolled in study which achieved less than 20/200 vision).
Our study confirms these trends with a longer duration of follow-up ( Table 2 ). In our series, patients with chemical burns and noncicatrizing graft failure attained vision of at least 20/200 in 100% and 73.1%, respectively. Of these patients, 100% and 89.5%, respectively, maintained vision of at least 20/200 at last follow-up (average follow-up 19 months). Our study did not include any patients with OCP, but 1 eye with Stevens-Johnson syndrome achieved 20/150 vision and maintained stable vision over 36 months of follow-up. Although no conclusions can be drawn from this anecdotal report of 1 patient with Stevens-Johnson syndrome, Boston type 1 keratoprosthesis implantation may provide an option in patients with bilateral corneal blindness from this condition despite its guarded long-term prognosis. 
Intraoperative Variables
Compared with the initial Boston Keratoprosthesis Study Group report, the pseudophakic type keratoprosthesis was used much more common and fewer concomitant procedures were performed. This is likely because of our smaller patient number, patient selection, and surgeon preference.
Glaucoma and Keratoprosthesis
Despite the technical limitations of intraocular pressure measurement after keratoprosthesis measurement, increased intraocular pressure was noted in a significant number of patients (8 eyes, 27%) ( Table 1 ). In most of these patients, the increase in intraocular pressure seen in the early postoperative period seemed to be transient and responded well to topical therapy. No surgical interventions for intraocular pressure control were required at last follow-up. This contrasts with the Boston Keratoprosthesis Study Group's initial report in which only 21 eyes (15%) had increased intraocular pressure postoperatively, and 7.8% (11 of 141 eyes) of eyes underwent a tube shunt. 7 
VA Outcomes
Consistent with previous reports, most patients had a significant increase in vision after Boston type 1 keratoprosthesis implantation. Patients without significant improvement or worsening of vision generally had underlying advanced glaucoma or other underlying posterior segment pathology.
Although our study does not provide a direct comparison to other alternatives for patients at high risk of corneal transplant failure, our data compare favorably published data both on AlphaCor keratoprosthesis (Addition Technology Inc, Des Plaines, IL) 9 and on repeat PK. 10 In our study, 75% of eyes at least 1 year after Boston type 1 keratoprosthesis implantation (average follow-up, 28 months) had BCVA of $20/200. This compares favorably with the Boston Keratoprosthesis Study Group's initial report in which 56.4% of eyes at least 1 year after surgery (average follow-up, 14.5 months) had BCVA of 20/200 or better (Fig. 4) .
In our study at UC Davis, at 1 year postoperatively, 25% of Boston type 1 keratoprosthesis eyes had BCVA of 20/40 or better. This is similar to the Boston Keratoprosthesis Study Group's initial report in which 22.6% of patients maintained this level of VA. Both reports compare favorably with the previously reported 16.9% after 1 repeat PK. 10 
Postoperative Complications and Management
In our study, retroprosthetic membrane was the most common postoperative complication occurring in 43% of eyes. The frequency of this complication in our patients was higher than the Boston Keratoprosthesis Study Group's initial report (25% of eyes) 7 and prior published data on the Boston type 1 keratoprosthesis (27%-35% of eyes) 8 and AlphaCor (9.3% of eyes). 11 In our study, the majority of retroprosthetic membranes required no treatment or were amenable to YAG laser treatment. Only 2 eyes had retroprosthetic membrane formation requiring surgical membranectomy, and only 1 eye underwent the procedure.
The reported incidence of retinal detachment in prior series of Boston keratoprosthesis patients varies from 3.5% to 12%. 7, 12 In our series, no patient developed a retinal detachment despite a longer duration of follow-up. In our series, sterile vitritis was seen in 1 patient (3%) and endophthalmitis in 3 eyes (10%). The incidence of endophthalmitis was more common than reported in the Boston Keratoprosthesis Study Group's initial report and of similar incidence to another prior report. 13 The previously reported association of endophthalmitis with patients with Stevens-Johnson syndrome was also seen in our study. 13 The low incidence of endophthalmitis in the Boston Keratoprosthesis Study Group's initial report may be related to the shorter length of follow-up.
Retention of the initial keratoprosthesis in our study was 83.3% (average follow-up, 19 months), which compares favorably with previously reported data on AlphaCor and repeat PK. 9, 10 The retention rate of the Boston Keratoprosthesis Study Group's initial report was 95% (average followup, 8.5 months), possibly related to the short duration of follow-up. Keratoprosthesis replacement was required more frequently in our study (16.7% of eyes) as compared with the Boston Keratoprosthesis Study Group's initial report (5%). Repeat keratoprosthesis replacement in our study was also more frequently encountered (10 vs ,1%). This increase may be because of longer follow-up and individual patient characteristics. Two of the 5 patients requiring keratoprosthesis replacement had autoimmune disease, Stevens-Johnson syndrome, and uncontrolled rheumatoid arthritis, and a third patient had Apert syndrome with severe exposure keratopathy despite large medial and lateral tarsorrhaphies. These characteristics likely predisposed these patients to this complication. After accounting for the device replacements, a keratoprosthesis was ultimately maintained in 96.7% of patients with only 1 patient requiring keratoprosthesis explantation. Continued follow-up is required to see whether the retention rate remains high.
In conclusion, the Boston type 1 keratoprosthesis is a viable option after multiple keratoplasty failures or in conditions with a poor prognosis for primary keratoplasty. All patients undergoing the procedure require close follow-up and ongoing maintenance. Patients with autoimmune ocular surface disease are at higher risk for complications. The UC Davis experience seems equivalent to the initial overall report of the Boston Keratoprosthesis Study Group. With longer follow-up, additional surgical procedures may be required but good anatomic and functional outcomes can be maintained.
